|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Pei-Jiun Chen | Pei-Jiun Chen | Pei-Jiun Chen | 03-6670880 | 7F., No. 66, Shengyi 2nd RdZhubei City, Hsinchu County, Taiwan | 2013/12/25 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Mycenax uses its process development technology and cGMP manufacturing capability in its biological products development and contract development services. Two products (TuNEX, Tumor Necrosis Factor Receptor-Fc and GranNEX, Granulocyte Colony Stimulating Factor) pursue Taiwan IND application in 2006 and start clinical trials in 2007. Other products, through cooperation with collaborators, in the pipeline includes Erithropoitin and anti-her2 human antibody products. Mycenax will expand its successful experiences to new protein drugs development. Mycenax specializes in strategic planning and execution, process development and manufacturing to accelerate the drug development process and minimize expenses. |
Market Information ( 2024/05/02 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
859.391 | 44.70 | 43.05 | 43.85 | 0.40 | 550 | .00 | 3,928 | 4 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/05/02) |
TPEx measures adopted (2024/05/02) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |